Cadrenal Therapeutics, Inc. Common Stock
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $7,632,843.
Profit Margin
| 2022 | 0 | -6.71M | |
|---|---|---|---|
| 2023 | 0 | -8.35M |
CVKD Income Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Revenue | ||
Revenue | 0 | 0 |
Cost of revenue | 1.98K | 1.26K |
Gross profit | -1.98K | -1.26K |
Operating exp. | ||
Research and development | 4.08M | 392.85K |
Selling and marketing | 0 | 0 |
Total operating expenses | 7.63M | 2.70M |
Operating income | -7.63M | -2.70M |
Other income (expenses), net | -724.24K | -4.01M |
Income before tax | -8.35M | -6.71M |
Income tax expense | 0 | 4 |
Net income | -8.35M | -6.71M |
Earnings per share | ||
Basic EPS | -9.63 | -0.58 |
Diluted EPS | -9.63 | -0.58 |
| Data source | Data source |